Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
483.23
-7.60 (-1.55%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings
October 29, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per...
Via
StockStory
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
October 29, 2025
From
United Therapeutics Corporation
Via
Business Wire
A Peek at United Therapeutics's Future Earnings
↗
October 28, 2025
Via
Benzinga
United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings
October 27, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
↗
September 02, 2025
Via
Stocktwits
This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside
↗
September 02, 2025
Via
Stocktwits
If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today
↗
October 21, 2025
Via
Benzinga
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
October 17, 2025
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market...
Via
MarketMinute
Topics
Retirement
United Therapeutics Corp (NASDAQ:UTHR) Meets Key Peter Lynch Investment Criteria
↗
October 16, 2025
United Therapeutics (UTHR) aligns with Peter Lynch's investment strategy, showing strong earnings growth, a fair PEG ratio, and a debt-free balance sheet for long-term value.
Via
Chartmill
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
October 15, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Prime Value Investment Candidate
↗
October 14, 2025
United Therapeutics (UTHR) is a strong value stock with a low P/E ratio, zero debt, high profitability, and solid growth, making it an undervalued biotech pick.
Via
Chartmill
1 Value Stock for Long-Term Investors and 2 Facing Headwinds
October 14, 2025
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...
Via
StockStory
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
October 13, 2025
From
United Therapeutics Corporation
Via
Business Wire
2 Growth Stocks with All-Star Potential and 1 Facing Headwinds
October 08, 2025
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Via
StockStory
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
September 26, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...
Via
Benzinga
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
September 19, 2025
From
United Therapeutics Corporation
Via
Business Wire
1 Momentum Stock to Target This Week and 2 We Brush Off
September 19, 2025
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...
Via
StockStory
3 Big Reasons to Love United Therapeutics (UTHR)
September 19, 2025
United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the...
Via
StockStory
Topics
Stocks
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Top Peter Lynch-Style GARP Investment
↗
September 17, 2025
United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health.
Via
Chartmill
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
September 16, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
September 12, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
↗
September 10, 2025
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.
Via
Investor's Business Daily
Topics
ETFs
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
↗
September 07, 2025
These ten large-cap stocks were top performers last week. Are they a part of your portfolio?
Via
Benzinga
United Therapeutics Corp (NASDAQ:UTHR): A Prime Value Investing Candidate with Strong Fundamentals
↗
September 06, 2025
United Therapeutics (UTHR) is a strong value investing candidate with low P/E, zero debt, high profitability, and excellent financial health, offering a solid margin of safety.
Via
Chartmill
Here are the top movers in Tuesday's session.
↗
September 02, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 02, 2025
Via
Benzinga
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results
↗
September 02, 2025
Via
Benzinga
Topics
Stocks
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.
↗
September 02, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
Why Is United Therapeutics Stock Rallying On Tuesday?
↗
September 02, 2025
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.
Via
Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
↗
September 02, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
